GlaxoSmithKiline seeks authorisation for type-2 diabetes treatment

FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has submitted a marketing authorisation application (MAA) for its albiglutide treatment to the European Medicines Agency (EMA).

FTSE-100 listed pharmaceutical giant GlaxoSmithKline (GSK) has submitted a marketing authorisation application (MAA) for its albiglutide treatment to the European Medicines Agency (EMA).

The product is an investigational once-weekly treatment for adult patients with type-2 diabetes which is not yet approved anywhere in the world.

The company also made a submission for albiglutide's regulatory application in the US.

Studies of albiglutide have shown that it rapidly degrades GLP-1, a peptide that is normally secreted from the gastrointestinal tract during a meal which in turn helps release insulin to control blood sugar elevations after eating, but which is reduced or absent in a person with type-2 diabetes.

GSK's share price was 0.48% higher at 1,480p by 13:15 Thursday.

NR

Recommended

Broker safety – your questions answered
Investment strategy

Broker safety – your questions answered

Cris Sholto Heaton answers more of your questions about the safety of stockbroker accounts
25 Mar 2020
How demographics affects stock valuations
Investment strategy

How demographics affects stock valuations

New research suggests that stock and bond valuations are driven by the age of the population – at least in the US.
24 Feb 2020
Do you own shares in Sirius Minerals? Here’s what you need to do now
Stocks and shares

Do you own shares in Sirius Minerals? Here’s what you need to do now

Mining giant Anglo American has proposed a cash takeover of Yorkshire-based minnow Sirius Minerals. Unhappy shareholders must decide whether to accept…
20 Feb 2020
Why investors should be “cautiously bullish” for 2020
Stockmarkets

Why investors should be “cautiously bullish” for 2020

Analysts have been out in force making rosy predictions for stockmarkets in 2020, but while there is certainly a case for optimism, investors should r…
17 Jan 2020

Most Popular

A simple way to profit from the next big trend change in the markets
Investment strategy

A simple way to profit from the next big trend change in the markets

Change is coming to the markets as the tech-stock bull market of the 2010s is replaced by a new cycle of rising commodity prices. John Stepek explains…
14 Jan 2021
Forget austerity – governments and central banks have no intention of cutting back
Global Economy

Forget austerity – governments and central banks have no intention of cutting back

Once the pandemic is over will we return to an era of austerity to pay for all the stimulus? Not likely, says John Stepek. The money will continue to …
15 Jan 2021
Here’s why markets have shrugged off the US political turmoil
Investment strategy

Here’s why markets have shrugged off the US political turmoil

Despite all the current political shenanigans in the US, markets couldn’t seem to care less. John Stepek explains why, and what it means for your mone…
7 Jan 2021